| Autor: |
Rodríguez-Cid, Jerónimo Rafael, Chards, Sonia Carrasco-Cara, González-Espinoza, Iván Romarico, García-Montes, Vanessa, Garibay-Díaz, Julio César, Hernández-Flores, Osvaldo, Riera-Sala, Rodrigo, Gozalishvili-Boncheva, Anna, Alatorre-Alexander, Jorge Arturo, Martínez-Barrera, Luis Manuel, Sánchez-Ríos, Carla Paola, Martinez-Camacho, Adriana, Martínez-Herrera, José Fabián, Guzmán-Casta, Jordi, Flores-Mariñelarena, Rodrigo Rafael, Diaz-Rico, Julián, Santillán-Doherty, Patricio |
| Zdroj: |
Lung Cancer Management; 20210101, Issue: Preprints |
| Abstrakt: |
Background:Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy. Materials and methods:This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness. Results:In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2–4.7 months) and an OS of 9 months (95% CI: 7.2–10.7 months). Conclusion:The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
